Phreesia, Inc. (NYSE:PHR) Receives $31.62 Average Price Target from Analysts

Shares of Phreesia, Inc. (NYSE:PHRGet Free Report) have received an average recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $31.62.

Several analysts recently weighed in on the company. Raymond James restated an “outperform” rating and set a $30.00 price target (up previously from $25.00) on shares of Phreesia in a report on Friday, March 15th. Truist Financial began coverage on Phreesia in a research report on Monday, February 26th. They set a “buy” rating and a $35.00 price objective on the stock. Robert W. Baird raised their price objective on Phreesia from $30.00 to $31.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $23.00 price objective on shares of Phreesia in a research report on Thursday, March 21st. Finally, JMP Securities raised their price objective on Phreesia from $28.00 to $30.00 and gave the company a “market outperform” rating in a research report on Thursday, March 21st.

Read Our Latest Stock Report on Phreesia

Phreesia Stock Up 2.9 %

Shares of PHR opened at $22.00 on Friday. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -8.63 and a beta of 0.95. Phreesia has a 1 year low of $12.05 and a 1 year high of $34.98. The business’s 50 day simple moving average is $22.96 and its 200-day simple moving average is $21.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.78 and a quick ratio of 1.78.

Phreesia (NYSE:PHRGet Free Report) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.02. Phreesia had a negative return on equity of 53.33% and a negative net margin of 38.42%. The business had revenue of $95.00 million for the quarter, compared to analysts’ expectations of $93.52 million. During the same period in the prior year, the firm earned ($0.72) EPS. The company’s revenue for the quarter was up 24.0% on a year-over-year basis. As a group, equities analysts expect that Phreesia will post -1.48 earnings per share for the current fiscal year.

Insider Transactions at Phreesia

In related news, General Counsel Allison C. Hoffman sold 5,549 shares of Phreesia stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $22.62, for a total transaction of $125,518.38. Following the transaction, the general counsel now owns 141,485 shares in the company, valued at $3,200,390.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Phreesia news, insider Janet Gunzburg sold 2,817 shares of Phreesia stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $23.27, for a total value of $65,551.59. Following the sale, the insider now owns 40,609 shares in the company, valued at $944,971.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Allison C. Hoffman sold 5,549 shares of Phreesia stock in a transaction on Monday, April 8th. The shares were sold at an average price of $22.62, for a total value of $125,518.38. Following the completion of the sale, the general counsel now owns 141,485 shares in the company, valued at approximately $3,200,390.70. The disclosure for this sale can be found here. Insiders have sold 82,467 shares of company stock valued at $1,895,776 over the last ninety days. Insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Several institutional investors and hedge funds have recently modified their holdings of the company. International Assets Investment Management LLC grew its stake in Phreesia by 1,987.3% during the 4th quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock worth $34,000 after purchasing an additional 1,411 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Phreesia during the 3rd quarter worth about $53,000. Russell Investments Group Ltd. boosted its position in shares of Phreesia by 5,462.3% during the 4th quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock worth $89,000 after acquiring an additional 3,769 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Phreesia during the 3rd quarter worth about $132,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Phreesia by 44.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,433 shares of the company’s stock worth $214,000 after acquiring an additional 3,518 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

About Phreesia

(Get Free Report

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

See Also

Analyst Recommendations for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.